Rallybio Corporation will deliver a presentation at the TD Cowen 45th Annual Health Care Conference on March 4, 2025 that will include the latest data on RLYB212, a monoclonal antibody treatment for fetal and neonatal alloimmune thrombocytopenia (FNAIT), according to a recent press release.
The conference is set to take place in Boston, MA from March 3rd to 5th. Dozens of companies representing various aspects of health care are expected to be in attendance. The conference will consist of fireside chats, panels, presentations and individual meetings with investors.
Typically, a vast range of topics are covered at the conference, including current and emerging trends in the health care sector, market forecasts and insights into various health services and technologies.
Read more about FNAIT therapies
Rallybio’s Chief Executive Officer, Stephen Uden, MD, will give a presentation on the company’s corporate structure. This is likely to include a discussion of Rallybio’s history, mission, business model and overarching strategy.
The presentation will begin at 1:10 p.m. EST. Interested parties can watch the presentation via a live webcast, which will be available online for about one month after the presentation.
Recently, Rallybio shared that it had begun dosing patients in its Phase 2 clinical trial evaluating the efficacy of RLYB212 in pregnant patients at risk for FNAIT. Preliminary results are expected later this year.
In addition to RLYB212, Rallybio is developing therapeutics to treat hypophosphatasia, diseases of iron overload, ophthalmological diseases and complemented-mediated diseases such as paroxysmal nocturnal hemoglobinuria and myasthenia gravis.
Sign up here to get the latest news, perspectives, and information about FNAIT sent directly to your inbox. Registration is free and only takes a minute.
